During the last session, Novabay Pharmaceuticals Inc (AMEX:NBY)’s traded shares were 1.02 million, with the beta value of the company hitting 2.05. The 52-week high for the NBY share is $1.52, that puts it down -1800.0 from that peak though still a striking 25.0% gain since the share price plummeted to a 52-week low of $0.06. The company’s market capitalization is $2.79M, and the average trade volume was 3.59 million shares over the past three months.
Novabay Pharmaceuticals Inc (AMEX:NBY) trade information
Novabay Pharmaceuticals Inc (NBY) registered a 0.39% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.39% in intraday trading to $0.08, hitting a weekly high. The stock’s 5-day price performance is -6.76%, and it has moved by -40.03% in 30 days. Based on these gigs, the overall price performance for the year is -94.52%.
Novabay Pharmaceuticals Inc (NBY) estimates and forecasts
Statistics show that Novabay Pharmaceuticals Inc has outperformed its competitors in share price, compared to the industry in which it operates. Novabay Pharmaceuticals Inc (NBY) shares have gone down -77.91% during the last six months, with a year-to-date growth rate more than the industry average at 87.76% against 10.20. In the rating firms’ projections, revenue will increase 0.50% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 3.28M as predicted by 2 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 3.58M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 24.47%. While earnings are projected to return 93.18% in 2024.
NBY Dividends
Novabay Pharmaceuticals Inc is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
